In this study, we investigated whether CD147 alters the efficacy of trastuzumab against HER2-positive cancer in both trastuzumab-sensitive and -resistant breast cancer cell lines via CD147 knockdown and preliminarily explored the underlying mechanism. This evidence concerns the gene BSG and breast carcinoma.